Introduction {#Sec1}
============

Neurotransmitter subtype specification in the developing forebrain depends in part on the temporal and spatial coordinates of local neuronal progenitor/precursor cells. These coordinates are achieved through the induction of specific sets of transcription factors in response to a variety of extrinsic cues. Understanding the intrinsic molecular mechanisms underlying precursor cell diversity is essential to understanding the genesis of the forebrain.

In the developing telencephalon, the majority of gamma-aminobutyric acid (GABA)-ergic interneurons arise from progenitor zones \[ventricular (VZ) and subventricular (SVZ) zones\] within the lateral, medial and caudal ganglionic eminences (LGE, MGE and CGE, respectively) of the basal ganglia anlage (subpallium). Newly generated GABAergic neurons exit the SVZ of these eminences and either radially migrate into the basal ganglia, where they largely differentiate into projection neurons, or tangentially migrate to dorsal structures of the pallium such as the cortex, hippocampus and olfactory bulb, where they differentiate into different subclasses of interneurons (Marin and Rubenstein [@CR42]; Wonders and Anderson [@CR60]; Ayala et al. [@CR5]\].

Four members of the mouse Dlx protein family (Dlx1, 2, 5 and 6), part of the Antennapedia class of non-Hox homeodomain transcription factors, are expressed in the embryonic subpallium (Panganiban and Rubenstein [@CR49]). Within this region, their expression overlaps with that of *Gad65* and *Gad67*, genes encoding different forms of the rate-limiting enzyme required for production of GABA from glutamate. In *Dlx1/2*^−/−^ double mutant mice, the tangential migration of GABAergic interneurons into pallial structures is nearly extinguished and neuronal precursors accumulate in the SVZ of the MGE and CGE (Anderson et al. [@CR1], [@CR2], [@CR3]; Yun et al. [@CR62]; Long et al. [@CR34]). These findings show that *Dlx* function is essential to the correct differentiation and migration of GABAergic interneurons.

Currently, little is known about the signaling pathways that modulate Dlx activity. In that regard, recent studies in non-neural cells have suggested the existence of functional interactions between Dlx proteins and Smad transcription factors, which are critical mediators of transforming growth factor-β (TGF-β) superfamily signaling pathways (Chiba et al. [@CR9]; Berghorn et al. [@CR7]). TGF-β superfamily members, including activin, bone morphogenetic protein (BMP), growth differentiation factor (GDF), Nodal, and TGF-β proteins, are secreted molecules that regulate an array of biological functions in many cell types (Shi and Massague [@CR54]; Derynck and Zhang [@CR14]; Massague et al. [@CR44]). They act by stimulating specific membrane serine/threonine receptor complexes, the activin-like kinase receptors, resulting in the phosphorylation and activation of regulatory Smads (R-Smads). Smads 1, 5 and 8 are mainly activated by BMP and GDF receptors, while Smads 2 and 3 are substrates for TGF-β, activin and Nodal receptors. Once activated, R-Smads accumulate in the nucleus where they associate with Smad4, a common partner for all R-Smads, to form transcription complexes. R-Smad:Smad4 complexes regulate transcription of a variety of genes through recruitment of other transcription factors, including coactivators or corepressors (Shi and Massague [@CR54]; Derynck and Zhang [@CR14]; Massague et al. [@CR44]).

Here we describe results that suggest an important role for TGF-β superfamily signaling in the development of telencephalic GABAergic neurons. Moreover, we provide *in vivo* evidence that Dlx and R-Smad proteins are co-expressed, physically interact, and localize to Dlx-regulated enhancers/promoters in the developing subpallium. Our results show further that Dlx proteins synergistically activate transcription from the promoter of a Dlx target gene. Together, these results suggest that TGF-β superfamily signaling and Dlx homeoproteins work together to promote telencephalic GABAergic neuron development.

Materials and methods {#Sec2}
=====================

DNA plasmids {#Sec3}
------------

The reporter plasmid containing the *LacZ* gene driven by the mouse *Dlx5/6* intergenic enhancer-i (*mI56i-LacZ*) (Zerucha et al. [@CR63]) was provided by Dr. Mark Ekker (University of Ottawa, Ottawa, ON). Vectors for expression of FLAG epitope-tagged human DLX2 and DLX5 were obtained by cloning the complete human cDNA sequences into pCAGGS/ES, a chicken β-actin promoter expression vector (Stuhmer et al. [@CR56], [@CR57]), using PCR primers containing the sequence of the FLAG epitope at the N-terminus. Expression vectors for the DLX2 (Ser7, Glu-Lys, and Ala-Thr) and DLX5 (Ser-Pro and Ser-Arg) mutant proteins identified in autistic patients were obtained using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). Plasmids pCAGGS-Dlx1 and pCAGGS-GFP were described elsewhere (Stuhmer et al. [@CR56], [@CR57]). Plasmids pCMV5B/FLAG-Smad1, pFLAG-Smad2, and pSmad4-HA (Attisano et al. [@CR4]; Macias-Silva et al. [@CR39]) were gifts from Drs. Jeffrey Wrana and Liliana Attisano (University of Toronto, Toronto, ON). Dominant negative mutant forms of Smad1, Smad2 and Smad4 (Zhang et al. [@CR64], [@CR66]) were provided by Dr. Rik Derynck (UCSF, San Francisco, CA).

Microarray analysis {#Sec4}
-------------------

RNA was extracted from embryonic stage (E) 15.5 basal ganglia dissected from either wild type or *Dlx1/2*^*−/−*^ mutants. Total RNA was isolated using the Absolutely RNA Miniprep kit (Stratagene). Twenty micrograms of pooled RNA from each genotype was used. Hybridization to Affymatrix 430 2.0 microarrays of the amplified and labeled cDNA was performed by the NIH Neuroscience Microarray Consortium (<http://arrayconsortium.tgen.org/np2/home.do>).

Animal procedures {#Sec5}
-----------------

Animal procedures were conducted in accordance with the guidelines of the Canadian Council for Animal Care and were approved by the Montreal Neurological Institute Animal Care Committee. Pregnant females were anesthetized in a CO~2~ chamber and euthanized by cervical dislocation. E15.5 embryos were recovered and their brains dissected and fixed with 4% paraformaldehyde in phosphate-buffered saline. After fixation, brains were cryoprotected by immersion in 30% sucrose, frozen-embedded in Tissue-Tek O.C.T. compound (Sakura Finetek U.S.A., Torrance, CA) and stored at −80°C. Frozen tissues were cryostat sectioned at 20 µm and mounted onto SuperFrost Plus slides (Fisher, Pittsburgh, PA).

In situ hybridization {#Sec6}
---------------------

*In situ* hybridization experiments were performed using digoxigenin-labeled riboprobes on frozen sections as described on the Rubenstein lab website (<http://www.ucsf.edu/jlrrlab/protocols.html>), using the following probes: *Dlx2*, *Gad67* (provided by Dr. Brian Condie, University of Georgia, Athens, Georgia), *Gdf11* (provided by Dr. Alexandra Joyner, Memorial Sloan Kettering Cancer Institute, New York, NY), *ActRIIb* (provided by Dr. Seung Kim, Stanford University, Stanford, CA) and *BMPR1A* (provided by Dr. Steve Harris, University of Texas Health Science Center at San Antonio, San Antonio, TX) (Bulfone et al. [@CR8]; Feijen et al. [@CR16]; Nakashima et al. [@CR46]; Maddox and Condie [@CR40]).

Immunohistochemistry {#Sec7}
--------------------

Analysis of E12.5 and E16.5 frozen sections was performed as described previously (Marin et al. [@CR43]), except that sections were heated for 30 min at 60°C in a 10 mM sodium citrate buffer. The following primary polyclonal antibodies were used either alone or in combination: rabbit anti-phosphorylated Smad2 (1:250; Millipore, Billerica, MA; catalog No. AB3849) and guinea pig anti-Dlx2 (Kuwajima et al. [@CR30]) (1:5,000; kindly provided by Dr. Kazuaki Yoshikawa, Osaka University, Osaka, Japan). The following secondary antibodies were used: Alexa Fluor 488 goat anti-rabbit IgG (H + L) (1:1000; Invitrogen, Carlsbad, CA; product No. A-11008), Cy3 AffiniPure F(ab′)2 Fragment Goat Anti-Guinea Pig IgG (H + L) (1:500, Jackson ImmunoResearch, West Grove, PA; code No. 106-166-003).

Chromatin immunoprecipitation {#Sec8}
-----------------------------

Cross-linked protein-DNA complexes from dissected E15.5 telencephalon were obtained as described previously (Zhou et al. [@CR67]). Approximately 1--2 × 10^7^ dissociated cells were cross-linked with 1% paraformaldehyde for 2 h at room temperature in the presence of protease inhibitors. Chromatin immunopreciptation was then performed using the Upstate Biotechnology (Millipore) Chromatin Immunoprecipitation Assay Kit (Cat. No. 17-295) following the manufacturer's instructions. The following antibodies were used for immunoprecipitation: anti-FLAG M2 (Sigma, St. Louis, MO, Cat. No. F1804), anti-Dlx2 (Porteus et al. [@CR50]), anti-Smad1 (A-4; Santa Cruz Biotechnology, Santa Cruz, CA, Cat. No. sc-7965 X), anti-phosphorylated Smad2 (Millipore; Cat. No. AB3849), anti-phosphorylated Smad2/3 (Ser 423/425) (Santa Cruz Biotechnology; Cat. No. sc-11769 X), and anti-Smad4 (C-20; Santa Cruz Biotechnology; Cat. No. sc-1909 X). The following oligonucleotides were used for polymerase chain reactions: Dlx1/2-F: 5′-CAGCTGCAAACCCAAGAGGG-3′; Dlx1/2-R: 5′-GCGCAGCAAATTTGGCTTTC-3′; Dlx5/6-F: 5′-GACATTGGGGACAATTTAAGG-3′; Dlx5/6-R: 5′-GCAATTTGTGTATGAATAAC-3′; Arx-F: 5′-CAAGCATGTAATTAAGTGAGC-3′; Arx-R: 5′-CCACTGGTACAATTGTCAAAT-3′; p21 distal-F: 5′-TATTGAATGTCGTGGTGGTGGTGA-3′; p21 distal-R: 5′-ACAGCACAGCCTCAGGACCCCACT-3′.

Co-immunoprecipitation {#Sec9}
----------------------

For analysis of endogenous proteins, extracts from dissected E15.5 telencephalon were subjected to immunoprecipitation using either rabbit anti-phosphorylated Smad2, mouse anti-FLAG, or rabbit anti-TrkB antibodies (Santa Cruz Biotechnology) (5 μg each per immunoprecipitation). Each immunoprecipitation contained 2 mg of tissue extract in 1 ml of Nonidet P-40 lysis buffer (10 mM Tris, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 10% glycerol) supplemented with a protease inhibitor mixture (Roche Products, Welwyn Garden City, UK). Imunoprecipitates, together with 1% of input lysate, were subjected to Western blotting analysis with a chicken anti-Dlx2 antibody, a custom-made affinity-purified antibody raised against a peptide corresponding to amino acids 133 to 146 of mouse Dlx2 (NNEPDKEDLEPEIR) (Aves Lab, Tigard, OR).

Transient transfection/transcription assays {#Sec10}
-------------------------------------------

COS cells were transfected using a calcium phosphate precipitation protocol. In all cases, the total amount of transfected DNA was adjusted to 2.5 µg per well. Assays were performed with 1.0 µg/transfection of reporter construct *mI56i-LacZ* in the presence or absence of the effector plasmids indicated in the figure legends (1.0 µg/transfection). In each case, 0.5 μg/transfection of a reporter plasmid containing the *luciferase* gene under the control of the *RSV* promoter was used as a control for transfection efficiency. Twenty-four hours after transfection, cells were subjected to determination of β-galactosidase and luciferase activity as described (Maira et al. [@CR41]). Results were expressed as mean values ± S.D.

Organotypic slice culture and electroporation {#Sec11}
---------------------------------------------

Preparation of 250 µm organotypic slice cultures from E12.5 forebrains and subsequent electroporation were performed as described (Stuhmer et al. [@CR57]). Focal expression of GFP and/or Smad1, 2 or 4 dominant negative mutants was achieved by pressure injecting the expression vectors (5 µg/µl) in the MGE or CGE. At least 16 slices were electroporated with each expression plasmids over 4 independent experiments. Electroporation was performed using 3 voltage pulses of 75 V with a duration of 5 ms using a GRASS SD9 stimulator with a 3 µF capacitor placed in parallel to generate exponential decay of current intensity over time. Slices were photographed using a fluorescent microscope after 12, 36, 60 and 84 h in order to detect GFP expression. To monitor the extent of cell death in the electroporated samples, slices were cultured for 48 h after electroporation, followed by fixation in 4% paraformaldehyde, cryoprotection by immersion in 30% sucrose, and embedding in Tissue-Tek O.C.T. compound. Frozen slices were cryostat sectioned at 20 µm and subjected to double-label immunofluorescence analysis using mouse anti-GFP (1:250; Novus Biologicals, Littleton, CO; catalog number NB-600597) and rabbit anti-active caspase 3 (1:500; BD Pharmingen, San Diego, CA; catalog number 557035) antibodies. Grayscale images were digitally adjusted to the appropriate green or red channels using Northern Eclipse software (Empix Imaging Inc., Missisauga, ON).

Results {#Sec12}
=======

Expression of TGF-β superfamily signaling components in the developing basal ganglia {#Sec13}
------------------------------------------------------------------------------------

A microarray analysis was performed to determine *TGF-*β pathway gene expression in the subpallium of E15.5 mouse embryos. The same analysis was also performed using *Dlx1*/*2*-deficient embryos (results are available at the NIH Neuroscience Microarray Consortium website <http://arrayconsortium.tgen.org/np2/home.do>) (Long et al. [@CR35]). We found that several components of TGF-β superfamily signaling were expressed in control embryos (Table [1](#Tab1){ref-type="table"}). These included members of both the BMP/GDF and TGF-β/activin/Nodal subfamilies. Most notably, transcripts expressing the common transcription factor Smad4, as well as Smad1/5 and Smad2 (from the BMP/GDF or TGF-β branches, respectively) were present in E15.5 subpallium, and their expression levels were comparable to those of *Dlx1*, *2* and *5*. Although the expression of some of those genes (notably *Gdf5*/*15*, *ALK-3* and *Smad3*) was slightly affected in *Dlx1*/*2*^*−/−*^ mutants, most of them were unchanged in mutant embryos, suggesting that expression of most TGF-β superfamily genes is not downstream of *Dlx* function (Table [1](#Tab1){ref-type="table"}). Table 1Microarray analysis of the expression of *TGF-β* superfamily components in the developing subpalliumValue WTValue *Dlx1/2*^*−/−*^A) BMP/GDF→ALK 1/2/3/6→Smad 1/5/8 pathway LigandGdfl06355Gdfl15738Gdfl55616Gdf24635Gdf34620Gdf94244Gdf53012ReceptorBMP-RIA (ALK-3)300491ActRI (ALK-2)281235ActRII236254ActRIIB230248BMP-RIB (ALK-6)7476BMPRII8293 SmadSmad420601837Smad1711729Smad5239205Smad74467B) TGF-β/activin Nodal→ALK4/5/7→Smad 2/3 pathway LigandTGFβ110881TGFβ25976TGFβ33813 ReceptorTGFβ-RI (ALK-5)638706TGFβ-RII3625ActRII236254ActRIIB230248 SmadSmad420601837Smad2283337Smad35814Smad74467C) Dlx transcription factors DlxDlx1123715Dlx22878Dlx570671Dlx614020Microarray gene expression analysis in the subpallium of E15.5 wild type and *Dlx1/2*^*−/−*^ mutants. Shown are genes of the *BMP*/*GDF* (*A*) and *TGF-β*/*activin*/*Nodal* (*B*) subfamilies. Each *TGF-β* superfamily member whose expression value was greater than 30 was included (genes expressed at values \>30 are generally detectable by *in situ* hybridization) (Long et al. [@CR35]). *C*, analysis of *Dlx* gene expression.

*In situ* hybridization experiments using coronal section through E15.5 mouse telencephalon were performed to confirm the microarray results and correlate the expression of selected TGF-β signaling genes to that of genes expressed in the basal ganglia (Supplemental Fig. [1](#AppESM1){ref-type="sec"}). *Dlx2* expression was detected throughout most of the subpallial telencephalon, notably in both the LGE and MGE. Within these structures, *Dlx2* was strongly expressed in the progenitor domains comprising both the VZ and the SVZ (Supplemental Fig. [1A--D](#AppESM1){ref-type="sec"}). As previously reported (Stuhmer et al. [@CR56], [@CR57]), *Gad67* expression closely resembled that of *Dlx2*, except that it was observed mostly in the SVZ and mantle zone (where postmitotic neurons are located) of the LGE and MGE (Supplemental Fig. [1E--H](#AppESM1){ref-type="sec"}). Expression analysis of representative members of the *BMP*/*GDF* signaling pathways, including ligands (*Gdf11*) and receptors (*ActRIIb* and *BMPR1A*), revealed overlapping expression with *Dlx2* and *Gad67* within the subpallium. *ActRIIb* and *BMPR1A* were strongly expressed in both the VZ and SVZ of the MGE and LGE (Supplemental Fig. [1M--T](#AppESM1){ref-type="sec"}), similar to the *Dlx2* subpallial expression. By contrast, *Gdf11* was mainly expressed in the SVZ of the LGE and MGE, similar to the expression of *Gad67* (Supplemental Fig. [1I--L](#AppESM1){ref-type="sec"}).

To determine whether Smad signaling is activated in the developing mouse basal ganglia, we subjected brain coronal sections to immunohistochemistry with antibodies against activated Smad2 (phosphorylated at serines 465 and 467). At both E12.5 (Fig. [1A--D](#Fig1){ref-type="fig"}; Supplemental Fig. [2](#AppESM1){ref-type="sec"}) and E16.5 (Fig. [1E--K](#Fig1){ref-type="fig"}), phosphorylated Smad2 (pSmad2) immunoreactivity was observed in the LGE, MGE, and CGE, where it localized mostly to the VZ and SVZ, with less robust but detectable expression in the mantle zone. Importantly, we observed co-expression of pSmad2 and Dlx2, detected using a previously described anti-Dlx2 antibody (Kuwajima et al. [@CR30]), in those regions (Fig. [1C, G, and K](#Fig1){ref-type="fig"},). Moreover, small numbers of cells co-expressing pSmad2 and Dlx2 were also observed in the lateral neocortex, along the trajectory normally occupied by tangentially migrating Dlx2-positive GABAergic neurons (Fig. [1D and K](#Fig1){ref-type="fig"}). Together, these findings provide evidence that the TGF-β superfamily pathway is activated in precursor cells and immature neurons of the subcortical telencephalon that also express Dlx proteins. Fig. 1Co-expression of activated Smad2 and Dlx2 in the developing basal ganglia. **A**--**D**, Double-labeling immunofluorescence analysis of the expression of phosphorylated Smad2 (pSmad2) (**A**) and Dlx2 (**B**) in coronal hemisections of E12.5 forebrain at caudal telencephalic level. **C**, Merged pSmad2 and Dlx2 staining: overlapping expression (yellow color) is visible in many cells in the CGE (large rectangle). **D**, High-magnification view of the area enclosed by the small rectangle in (**C**): arrowheads point to cells co-expressing pSmad2 and Dlx2 in the neocortex. **E**--**K**, Expression of pSmad2 (**E**, **H** and **I**) and Dlx2 (**F** and **J**) in coronal hemisections of E16.5 telencephalon at rostral (**E**--**G**) or mid-telencephalic (**H**--**K**) positions. Merged staining is shown in (**G** and **K**). **I**--**K**, High-magnification views of the boxed area in (**H**). Overlapping expression of pSmad2 and Dlx2 was detected in the LGE and MGE, as well as in migrating GABAergic neurons in the neocortex (arrowheads in panel K). CGE, caudal ganglionic eminence; Cx, neocortex; IZ, intermediate zone; LGE, lateral ganglionic eminence; LV, lateral ventricle; MGE, medial ganglionic eminence; Se, septum

Functional interaction between Dlx and Smad transcription factors {#Sec14}
-----------------------------------------------------------------

Previous studies have suggested that Dlx and Smad proteins interact in non-neural cells (Chiba et al. [@CR9]; Berghorn et al. [@CR7]). Based on our finding that Dlx and activated Smad expression overlaps in the developing basal ganglia, we tested if Smad factors might interact with Dlx homeoproteins in the developing telencephalon. E15.5 mouse embryo telencephalic extracts were subjected to immunoprecipitation with either anti-phosphorylated Smad2 or control antibodies, followed by Western blotting analysis with anti-Dlx2 antibodies. These studies showed that endogenous Dlx2 was co-immunoprecipitated with activated Smad2 (Fig. [2A](#Fig2){ref-type="fig"}, lane 4), but not when control antibodies were used (Fig. [2A](#Fig2){ref-type="fig"}, lanes 2 and 3). These results show that Dlx2 and activated Smad2 interact *in vivo*. Fig. 2Physical and functional interaction between Dlx and Smad transcription factors. **A**, *In vivo* co-immunoprecipitation. Extracts obtained from dissected E15.5 telencephalon were subjected to immunoprecipitation with anti-phosphorylated Smad2 (lane 4) or control (lane 2 and 3) antibodies, as indicated. Immunoprecipitates, together with 1% of input lysate (lane 1), were subjected to Western blotting with a chicken anti-Dlx2 antibody. The position of migration of the immunoglobulin light chain (IgG LC) is indicated. **B**, Chromatin immunoprecipitation. Protein-DNA complexes from dissected E15.5 telencephalon were subjected to immunoprecipitation with the indicated antibodies, followed by PCR with oligonucleotide primers specific for the *Dlx1/2*, *Dlx5/6* and *Arx* enhancers or the *p21*^*Cip1*^ distal promoter. Dlx2, Smad1, Smad2/3, and Smad4 were associated with the *Dlx1/2*, *Dlx5/6* and *Arx* enhancers, but not with the distal region of the *p21*^*Cip1*^ promoter. Total genomic DNA was used as a positive control (Input). **C**, Transient transcription assays. The effect of Smad1, Smad2 or Smad4 on Dlx1-, Dlx2- and Dlx5-mediated transcriptional activity was assessed by co-transfecting COS cells with a LacZ reporter plasmid driven by the *Dlx5/6* enhancer-i (*mI56i-LacZ*). Results are shown relative to the activity of the reporter alone and represent the means ± the S.D. of at least four experiments performed in duplicates (\*, *p *\< 0.05 using one-way analysis of variance with a Dunnett's post test). A reporter plasmid containing the *luciferase* gene under the control of the *RSV* promoter was used as a control for transfection efficiency

To determine whether Dlx5 can also interact with Smad2, co-immunoprecipitation studies were performed using extracts from COS cells transfected with constructs encoding epitope-tagged FLAG-Smad2 or HA-Smad4 in combination with FLAG-tagged human DLX5 (throughout this paper, "Dlx" is used to refer to mouse proteins and "DLX" to indicate human proteins). Immunoprecipitations using a rabbit antibody raised against DLX5 revealed that Smad2 co-immunoprecipitated with DLX5 (Supplemental Fig. [3](#AppESM1){ref-type="sec"}). In agreement with previous reports (Chiba et al. [@CR9]; Berghorn et al. [@CR7]), no interaction between Smad4 and DLX5 was detected (Supplemental Fig. [3](#AppESM1){ref-type="sec"}).

Chromatin immunoprecipitation studies using E15.5 telencephalon were performed next to determine whether both Dlx and Smad proteins would localize *in vivo* to the regulatory regions of genes regulated by Dlx factors (Zerucha et al. [@CR63]; Ghanem et al. [@CR20]; Colasante et al. [@CR11]; Potter et al. [@CR51]). Using a panel of different anti-Smad antibodies and previously characterized Dlx2 antibodies (Zhou et al. [@CR67]; Porteus et al. [@CR50]), we found that Dlx2, Smad1, Smad2/3, and Smad4 were associated with the *Dlx1/2*, *Dlx5/6* and *Arx* enhancers in the E15.5 telencephalon (Fig. [2B](#Fig2){ref-type="fig"}).

Transient transfection assays were then conducted to determine whether Dlx and Smad proteins would regulate together transcription from a telencephalic enhancer. COS cells were transfected with a plasmid containing a *LacZ* reporter gene under the control of the *Dlx5*/*6* intergenic enhancer (Zerucha et al. [@CR63]) in combination with various DLX and/or Smad expression plasmids. DLX2, and also DLX1 and DLX5, activated transcription of the reporter gene 5--10 fold (Fig. [2C](#Fig2){ref-type="fig"}). Expression of Smad1, Smad2 or Smad4 alone had no significant effect on reporter gene expression, suggesting that Smad transcription factors do not directly bind the *Dlx5*/*6* enhancer or that they require the presence of transcriptional partners to activate transcription upon binding. However, when co-expressed in combination with DLX5, DLX2, and to a lesser degree DLX1, both Smad1 and Smad2 significantly enhanced DLX-dependent transcriptional activation, whereas Smad4 had little or no effect (Fig. [2C](#Fig2){ref-type="fig"}). We observed no increased DLX affinity for DNA in the presence of Smad in electrophoretic mobility shift assays (data not shown).

Taken together, these results indicate that Smad and Dlx proteins are co-expressed and interact in cells of the developing telencephalon. Moreover, they localize to enhancer/promoters of telencephalic genes *in vivo*, and can co-operatively activate transcription. These findings provide evidence that Smad and Dlx proteins functionally interact to promote activation of telencephalic gene expression *in vivo*.

Distinct effects of naturally occurring DLX mutations from autistic patients on Smad-dependent potentiation of DLX transcriptional activity {#Sec15}
-------------------------------------------------------------------------------------------------------------------------------------------

Previous evidence suggests a role for DLX proteins in human neuropsychiatry disorders, such as autism. For instance, mice lacking *Dlx1* exhibit loss of subsets of local cortical circuit neurons and develop epilepsy, a malady commonly seen in the autistic population (Cobos et al. [@CR10]). In addition, the human *DLX* bigene clusters are located on chromosomes 2q31.1 (*DLX 1/2*) and 7q21 (*DLX 5/6*), which are both autism susceptibility loci as determined by independent linkage studies (Consortium IMGSoA [@CR12]; Bacchelli et al. [@CR6]; Hutcheson et al. [@CR27]). Furthermore, sequencing of *DLX* genes in autistic patients and non-autistic siblings led to the identification of three non-synonymous mutations in DLX2 ("Ser7", "Glu-Lys", and "Ala-Thr") and two in DLX5 ("Ser-Pro" and "Ser-Arg") in autistic individuals (Hamilton et al. [@CR22]) (Fig. [3A](#Fig3){ref-type="fig"}). Fig. 3Effect of Smad proteins on the transcriptional activity of mutated DLX proteins found in autistic individuals. **A**, Schematic representation of the location of the DLX2 and DLX5 mutations identified in autistic individuals. Note that all mutations occur in regions of homology between DLX proteins. The DLX2 serine insertion (Ser7) is in the DllA domain conserved in the DLX2/3/5 subgroup (green boxes), the DLX2 glutamic acid to lysine (Glu-Lys) mutation is in a conserved region flanking the homeodomain of the *DLX2/3/5* subgroup (blue boxes), while the DLX2 alanine to threonine (Ala-Thr) and both DLX5 serine to proline (Ser-Pro) and serine to arginine (Ser-Arg) mutations occur in a proline-rich domain conserved in all six mammalian DLX proteins (yellow boxes). **B**, Expression of wild type (WT) and mutant DLX proteins. COS cells were transfected with plasmids expressing the indicated proteins, followed by Western blot analysis with an anti-FLAG antibody. **C**, Transient transcription assays. COS cells were transfected with a *LacZ* reporter plasmid driven by the *Dlx5/6* enhancer-i in the absence or presence of the indicated combinations of proteins. All DLX2 mutants behaved like wild type DLX2 in these assays in the absence or presence of Smad proteins. By contrast, Smad co-expression did not enhance DLX5 Ser-Pro-mediated transcriptional activity, while the DLX5 Ser-Arg mutant exhibited an impaired transcriptional interaction with Smad2. Results are shown relative to the activity of the reporter alone and represent the means ± the S.D. of at least four experiments performed in duplicates (\*, *p *\< 0.05 using one-way analysis of variance with a Dunnett's post test)

To determine whether the DLX2 and/or DLX5 mutations characterized in autistic patients might affect the interaction between Smad and DLX proteins, we introduced those mutations into the human *DLX2* or *DLX5* cDNA sequences by site-directed mutagenesis. All of the mutated proteins exhibited similar expression levels when transfected in COS cells (Fig. [3B](#Fig3){ref-type="fig"}). Moreover, in dose-dependent transient transfection/transcription assays, all DLX2 and DLX5 mutants retained the ability to activate transcription (Supplemental Fig. [4A](#AppESM1){ref-type="sec"}). The DLX2 mutants exhibited a trend towards a stronger transcriptional activity than wild type DLX2, but this was not statistically significant. EMSA analysis indicated no alteration in DNA binding for any of the DLX mutants (Supplemental Fig. [4B](#AppESM1){ref-type="sec"}).

The transcriptional activity of the DLX2 mutants was enhanced by Smad1 and Smad2, similarly to wild-type proteins (Fig. [3C](#Fig3){ref-type="fig"}). By contrast, both DLX5 mutants exhibited impaired functional interaction with Smad factors. More specifically, the transcriptional activity of the DLX5 Ser-Pro mutant was not potentiated by either Smad1 or Smad2, while the DLX5 mutant Ser-Arg was not responsive to Smad2-mediated transcriptional potentiation (Fig. [3C](#Fig3){ref-type="fig"}). Together, these results suggest that DLX mutations identified in autistic patients do not perturb DLX DNA binding and transcriptional activity but have different effects on DLX:Smad interactions.

Inhibition of tangential cell migration from the basal ganglia to the cortex by blockage of TGF-β superfamily signaling {#Sec16}
-----------------------------------------------------------------------------------------------------------------------

*Dlx* genes are essential for the proper migration of GABAergic interneurons from the subpallial SVZ to the neocortex (Anderson et al. [@CR1], [@CR2], [@CR3]). Smad and Dlx proteins are co-expressed in the basal ganglia and in cells located in the lateral neocortex, likely corresponding to tangentially migrating GABAergic neurons (Fig. [1](#Fig1){ref-type="fig"}). Moreover, Smad and Dlx proteins interact in the developing telencephalon and localize to common DNA sequences *in vivo* (Fig. [2](#Fig2){ref-type="fig"}). Based on these observations, we examined whether TGF-β signaling is involved in GABAergic interneuron development. More specifically, we tested if inhibition of TGF-β signaling in the embryonic subcortical telencephalon would phenocopy the accumulation of immature interneurons in the SVZ of the MGE and CGE observed in *Dlx1*/*2* null mutants. Organotypic slices from the brain of wild-type E12.5 mouse embryos were prepared from different levels of the rostro-caudal axis and focally electroporated in the VZ/SVZ of the MGE or CGE with a combination of dominant-negative Smad mutants (Smad-DN) and GFP expression vectors. Controls involved electroporation of GFP alone ('control side'). Slices were then cultured and the tangential migration of the electroporated cells was monitored 12, 36, 60 and 84 h after electroporation.

To interfere with both branches of TGF-β superfamily signaling, organotypic slices were electroporated with a previously described (Zhang et al. [@CR64], [@CR66]) dominant-negative form of Smad4 (the obligatory partner for all R-Smads). Compared to exogenous expression of GFP alone, expression of Smad4-DN in the MGE or CGE completely abrogated the tangential migration of the electroporated cells to the cortex (Fig. [4](#Fig4){ref-type="fig"}). Forced expression of Smad4-DN did not cause a notable increase in cell death, detected using an antibody against active caspase 3 (Supplemental Fig. [5](#AppESM1){ref-type="sec"}). This result suggests that the impaired tangential migration caused by the expression of Smad4-DN was not the result of decreased survival of the electroporated cells. Similar experiments were performed using dominant-negative forms of Smad1 and Smad2 (Zhang et al. [@CR64], [@CR66]) to specifically block either BMP/GDF subfamily or TGF-β/activin/Nodal subfamily signaling, respectively. Expression of both Smad1-DN and Smad2-DN in the MGE or CGE also resulted in impaired tangential migration, compared to control conditions (Fig. [5](#Fig5){ref-type="fig"}). Each dominant-negative form alone had a weaker effect than Smad4-DN, consistent with only a partial inhibition of TGF-β superfamily signaling in either case. Taken together with the results depicted in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, these findings provide evidence that TGF-β superfamily signaling is important for neuronal cell migration from the subpallium to the cortex. Moreover, they suggest the existence of a functional interaction between Dlx and TGF-β signaling pathways in the regulation of telencephalic GABAergic neuron development. Fig. 4Role for TGF-β signaling in tangential migration of GABAergic interneurons in the developing telencephalon. Organotypic cultures of E12.5 forebrain slices from different levels of the rostrocaudal axis were focally electroporated into the MGE or CGE with a GFP expression vector alone (left hemisphere; panels a-l) or with a combination of GFP and dominant-negative Smad4 (Smad4-DN) (right hemisphere; shown in each case in panels a′-l′). Slices were photographed after 12, 36, 60 and 84 h to visualize the tangential migration of GFP-expressing (i.e., electroporated) cells away from the MGE or CGE. A significant decrease of cell migration towards the neocortex was observed in the hemisphere electroporated with Smad4-DNFig. 5Role for both branches of TGF-β signaling in tangential migration of GABAergic interneurons in the developing telencephalon. Organotypic cultures of E12.5 forebrain slices from different levels of the rostrocaudal axis were focally electroporated into the MGE or CGE with a GFP expression vector alone (left hemisphere; panels a-l) or with a combination of GFP and dominant-negative Smad1 (Smad1-DN) (**A**) or dominant negative Smad2 (Smad2-DN) (**B**) (right hemisphere; shown in each case in panels a′-l′). Slices were photographed after 12, 36, 60 and 84 h to visualize the tangential migration of GFP-expressing cells from the MGE or CGE. Decreased cell migration towards the neocortex was observed in the hemisphere electroporated with dominant-negative Smad forms

Discussion {#Sec17}
==========

Using a combination of expression studies and *ex vivo* electroporation assays, we provided evidence that both branches of TGF-β signaling are active in developing ganglionic eminences and that dominant-negative inhibition of Smad activity in the basal ganglia impairs tangential neuronal migration to the cortex. In agreement with the demonstration that blocking Smad signaling phenocopies the GABAergic interneuron migration defect observed in *Dlx1/2*-deficient mice, we also demonstrated that Dlx and Smad proteins are co-expressed, interact, and localize to common gene regulatory sequences in the developing telencephalon. Moreover, they co-activate transcription from a telencephalic enhancer *in vitro*. These results suggest a cross-talk between TGF-β signaling and Dlx proteins during development of telencephalic GABAergic neurons.

Activation of TGF-β signaling in the developing basal ganglia {#Sec18}
-------------------------------------------------------------

TGF-β signaling pathways perform critical roles during a variety of developmental processes, including functions important for brain patterning and differentiation (Liem et al. [@CR32]; Crossley et al. [@CR13]; Panchision et al. [@CR48]; Hebert et al. [@CR25], [@CR26]; Seoane et al. [@CR53]; Fernandes et al. [@CR18]). Several previous studies suggest roles for TGF-β signaling in dorsal forebrain development. For instance, *Bmp2/4/5/6/7* are expressed in the embryonic dorsomedial telencephalon, a region that gives rise to the cortical hem and the choroid plexus*.* In this region, those BMP proteins induce *Msx1* and repress *Foxg1* gene expression, thus inhibiting progenitor cell proliferation (Furuta et al. [@CR19]; Shimamura and Rubenstein [@CR55]; Ohkubo et al. [@CR47]). A role for BMP signaling in the dorsal telencephalon is also suggested by the conditional mutation of BMP receptors, which results in loss of the choroid plexus (Hebert et al. [@CR25], [@CR26]; Fernandes et al. [@CR18]). In contrast, relatively little is known about the role of the TGF-β pathway during development of the basal ganglia and GABAergic neurons.

To begin to determine whether TGF-β superfamily signaling is important for the development of the subpallium, we analyzed the basal ganglia RNA expression of components from both *TGF-β* signaling sub-pathways, including ligands, receptors and Smad transcription factors. Our findings show that genes encoding several TGF-β superfamily ligands, including Gdf11, are expressed in the basal ganglia. This observation extends previous reports describing the forebrain expression of certain members of this secreted protein family, including *Bmp7* (Tole et al. [@CR58]), *Bmp9* (Lopez-Coviella et al. [@CR36]), and *Bmp2/4/6* (Hattori et al. [@CR24]; Gratacos et al. [@CR21]). Our results also show that type I and type II receptors for both TGF-β sub-pathways are expressed in the subpallium. This finding confirms previous reports showing that most BMP/GDF subfamily receptors are detected in the developing basal ganglia (Lopez-Coviella et al. [@CR36]; Hattori et al. [@CR24]; Gratacos et al. [@CR21]). We also detected expression of *Smad1, Smad5*, *Smad2*, as well as *Smad4*, in the subpallium, where they exhibit expression levels similar to those of the *Dlx* genes. In contrast, *Smad3* and *Smad7* appear to be only weakly expressed in the basal ganglia. Similar observations were made in septum-derived cells, albeit at different developmental stages (Lopez-Coviella et al. [@CR36]).

We showed further that phosphorylated (activated) Smad1 (data not shown) and Smad2 (this study) are present in the developing basal ganglia. Importantly, phosphorylated Smad2 expression exhibits a regional and cellular overlap with Dlx2 expression in the subpallium, suggesting that Smad2 is activated in developing telencephalic GABAergic neuronal precursors that express Dlx2 (Anderson et al. [@CR3]; Eisenstat et al. [@CR15]). Certain Dlx2-positive cells did not appear to express activated Smad2. This observation could be due to the fact that activated Smad3 and/or Smad1/5 might be expressed in those cells and play a role similar to that of phosphorylated Smad2. Alternatively, Smad2 might not be phosphorylated in all cells expressing Dlx2. Importantly, we also observed the presence of cells co-expressing phosphorylated Smad2 and Dlx2 in the neocortex, likely corresponding to tangentially migrating interneurons, suggesting an involvement of TGF-β signaling in tangential interneuron migration. Together, these findings correlate activated Smad2 expression with sequential stages of telencephalic GABAergic neuronal development.

Functional interaction between Dlx and Smad transcription factors {#Sec19}
-----------------------------------------------------------------

Prior to the present study, little was known about the molecular mechanisms underlying Dlx activity during basal ganglia development. Previous information was limited to the observation that Dlx and Msx1/Msx2 homeoproteins interact to mediate a mutual inhibition of their DNA binding activities and transcriptional functions (Panganiban and Rubenstein [@CR49]; Zhang et al. [@CR65]). In the present study, we tested the possibility of a cross-talk during basal ganglia development between Dlx and TGF-β pathways based on the overlapping expression of Dlx and activated Smad proteins in the subpallium and the observation that certain Dlx and Smad family members interact in non-neural cells (Chiba et al. [@CR9]; Berghorn et al. [@CR7]). Using both *in vivo* protein-protein interaction studies and transcription assays in transfected cells, we found that Smad transcription factors physically interact, and co-activate transcription from a telencephalic enhancer, with Dlx proteins. Moreover, chromatin immunoprecipitation studies showed the *in vivo* localization of both Dlx and Smad proteins to a number of telencephalic enhancers/promoters that are known to be dependent on Dlx1/2 function (Zerucha et al. [@CR63]; Ghanem et al. [@CR20]; Colasante et al. [@CR11]; Potter et al. [@CR51]). These findings strongly suggest that Smad and Dlx proteins participate in common mechanisms during subcortical telencephalon development, shedding new light into the molecular events underlying Dlx function during forebrain development.

Our finding that Dlx1/2/5 and Smad1/2 co-operate to promote transcriptional activation from the enhancer of a telencephalic gene does not appear to result from an increased affinity (or stabilization) of Dlx binding to its DNA target element. EMSA experiments performed using a probe containing a Dlx-binding motif from the mouse *Dlx5*/*6* enhancer-i (Zhou et al. [@CR67]) showed that Dlx DNA binding was not affected by co-expression of Smad1, Smad2 or Smad4 (data not shown). It is possible that enhancement of Dlx-mediated transactivation by Smad is the result of a more efficient recruitment of transcriptional co-activators. Potential Dlx co-activators include the PDZ protein, GRIP1 (Yu et al. [@CR61]), Dlxin-1 (Masuda et al. [@CR45]), and Necdin (Kuwajima et al. [@CR30]), while CBP/p300 transcription factors are believed to be co-activators for Smads (Feng et al. [@CR17]; Janknecht et al. [@CR28]). It should be noted that our observation of a transcriptional co-operation between Dlx and Smad proteins on a telencephalic promoter is in contrast with studies showing that Dlx1/Smad4 and Dlx3/Smad6 interactions result in antagonistic transcriptional effects in non-neural cells (Chiba et al. [@CR9]; Berghorn et al. [@CR7]). For instance, previous studies suggested that Dlx1 interferes with TGF-β pathways by binding to Smad4 and sequestering transcriptional co-activators from Smad3/Smad4 heterodimers (Chiba et al. [@CR9]). This discrepancy might be explained by different promoter/enhancer contexts and/or contrasting molecular properties of different Dlx/Smad complexes.

Protein phosphorylation might represent an additional mechanism modulating Smad/Dlx cross-talk. BMP2 stimulation of osteoblasts elicits the phosphorylation of Dlx5 by the p38 kinase pathway (Ulsamer et al. [@CR59]). Given that Smads are known to be regulated by various kinase pathways (Massague et al. [@CR44]), including p38 signaling, it is possible that a single extracellular stimulus might regulate the phosphorylation state of both Dlx and Smad proteins and thus synchronously regulate their transcriptional activity. In this regard, our observation that Smad proteins did not enhance transactivation mediated by the DLX5 Ser-Pro and Ser-Arg mutants identified in autistic individuals is intriguing given that serine residues are affected in each case. Future studies are needed to test whether those serines might be kinase substrates. It is also plausible that DLX5 mutants/Smad heteromers fail to recruit the appropriate co-activators.

Role for TGF-β signaling in telencephalic GABAergic neuron differentiation {#Sec20}
--------------------------------------------------------------------------

The functional interaction between Dlx and Smads, in addition to the similarities in the expression pattern of Dlx2 and activated Smad2, as well as *Gad67* and various components of *TGF-β* pathways, suggested a role for TGF-β signaling in GABAergic neuron differentiation. We tested this possibility by performing *ex vivo* loss of function studies based on the electroporation of dominant negative forms of Smad1, Smad2, and Smad4 in organotypic brain slices. Expression of those dominant negative mutants in the developing basal ganglia phenocopied the defects in tangential migration observed in *Dlx1/2*-deficient mice. Smad1 and Smad2 dominant negative mutants partially blocked tangential neuron migration, whereas inhibition of Smad4 nearly completely blocked migration. These results suggest that both the BMP/GDF and TGF-β/activin/Nodal pathways play a role in that process, resulting in a partial functional redundancy between sub-pathways.

A role for TGF-β signaling in GABAergic neuron differentiation is in agreement with the observation that BMP2 promotes survival and differentiation of cultured striatal GABAergic neurons (Hattori et al. [@CR24]) and that BMP6 is a neurotrophic factor for calbindin-positive (GABAergic) striatal neurons (Gratacos et al. [@CR21]). TGF-β signaling might also be implicated in the differentiation of other neuronal subtypes in the basal ganglia. This has been postulated for BMP9, which is expressed in the developing striatum and appears to regulate cholinergic neuron differentiation (López-Coviella et al. [@CR37]). It is also worth noting that there is evidence that BMPs regulate expression of *Dlx2* and *Dlx5* during bone and feather bud development (Luo et al. [@CR38]; Harris et al. [@CR23]; Kim et al. [@CR29]; Rouzankina et al. [@CR52]; Levi et al. [@CR31]; Liu et al. [@CR33]). While Dlx function may not strongly regulate expression of TGF-β signaling components in the embryonic mouse basal ganglia, we cannot rule out that Dlx transcription factors regulate these genes in other tissues.

In conclusion, the characterization of a functional interaction between Dlx proteins and TGF-β signaling pathways is expected to provide new insight into the regulation of the expression of GABAergic phenotype-specific genes. It will also facilitate the characterization of a number of other developmental mechanisms where the expression of members of these protein families overlaps.
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